Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC Products

Abstract The number of mesenchymal stromal/stem cell (MSC) therapeutics and types of clinical applications have greatly diversified during the past decade, including rapid growth of poorly regulated “Stem Cell Clinics” offering diverse “Unproven Stem Cell Interventions.” This product diversification...

Full description

Saved in:

Bibliographic Details
Published in:	Stem cells translational medicine Vol. 11; no. 1; pp. 2 - 13
Main Authors:	Moll, Guido, Ankrum, James A, Olson, Scott D, Nolta, Jan A
Format:	Journal Article
Language:	English
Published:	US Oxford University Press 03.03.2022
Subjects:	Blood Coagulation Case reports Clinical trials Humans Mesenchymal Stem Cell Transplantation - adverse effects Mesenchymal Stem Cells - metabolism Patient safety Stem cells Therapeutic applications Thromboembolism Thromboplastin - metabolism Tissue factor mesenchymal stromal/stem cells (MSCs) product diversification hemocompatibility thromboembolism safety and efficacy coagulopathy cellular therapy tissue source coagulation tissue factor/CD142/Factor III/F3
ISSN:	2157-6564, 2157-6580, 2157-6580
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!